Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing rasagiline

A technology of composition and mixture, which is applied in the direction of drug combination, medical preparations of non-active ingredients, pharmaceutical formulas, etc., and can solve problems such as allergic reactions and diarrhea

Inactive Publication Date: 2008-04-02
BEIJING D VENTUREPHARM TECH DEV
View PDF3 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, oral administration of large amounts of mannitol can cause diarrhea and allergic reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Preparation Process:

[0025] 1. Crush and sieve the raw and auxiliary materials, and set aside.

[0026] 2. Weigh the prescribed amount of rasagiline mesylate, mannitol, microcrystalline cellulose, and starch and mix them evenly according to the principle of equal addition to obtain a solid mixture.

[0027] 3. Add starch slurry to the solid mixture to granulate, dry and granulate.

[0028] 4. Calculate the yield, add micropowder silica gel, talcum powder, stearic acid, mix, and pack into capsules.

Embodiment 2

[0031] Preparation Process:

[0032] 1. Crush and sieve the raw and auxiliary materials, and set aside.

[0033] 2. Weigh the prescribed amount of rasagiline mesylate, sorbitol, microcrystalline cellulose, precrossified starch, and starch and mix them uniformly according to the principle of equal incremental addition to obtain a solid mixture.

[0034] 3. Add starch slurry to the solid mixture to granulate, dry and granulate.

[0035] 4. Calculate the yield, add micropowder silica gel, talcum powder, citric acid, mix, and compress into tablets.

Embodiment 3

[0038] Preparation Process

[0039] 1. Crush and sieve the raw and auxiliary materials, and set aside.

[0040] 2. Weigh the rasagiline mesylate, mannitol, microcrystalline cellulose, and carboxymethyl starch sodium in the prescribed amount and mix them uniformly according to the principle of equal increase to obtain a solid mixture.

[0041] 3. Add 50% ethanol to the solid mixture to granulate, dry and granulate.

[0042] 4. Calculate the yield, add essence, sucralose, menthol, magnesium stearate, citric acid, mix well, and press into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses an oral solid medicinal combination, comprises 0.5 weight percent to 3 weight percent of rasagiline and salt of rasagiline, less than 60 weight percent of pentahydric alcohol and / or hexahydric alcohol and 0.5 weight percent to 3 weight percent of organic acid. The present invention is used for curing the Parkinsonism.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a novel rasagiline oral solid pharmaceutical composition for treating Parkinson's disease. Background technique [0002] Parkinson's disease is the second largest neurological chronic disease after Alzheimer's disease. The onset of Parkinson's disease is mainly due to the progressive degeneration of dopaminergic neurons in the substantia nigra-striatum system of the brain, resulting in striatum Depletion of the neurotransmitter dopamine in the major motor areas of the brain. [0003] The current drugs for the treatment of Parkinson's disease include levodopa, DA receptor agonists, MAO-B inhibitors, and COMT inhibitors. Since the 1960s, levodopa has always been the main force in the treatment of Parkinson's disease. Although levodopa has its irreplaceable advantages, it is only used as a precursor of DA to supplement DA content, which is prone to serious complications. disease. C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K9/48A61K31/13A61K47/38A61P25/16
Inventor 岳本花
Owner BEIJING D VENTUREPHARM TECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com